Trial of Suvorexant for Sleep in Children With Autism
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effect of suvorexant on sleep in children and
adolescents with Autism Spectrum Disorder (ASD). Suvorexant is a selective, dual orexin
receptor antagonist (DORA) used for the treatment of sleep onset difficulties and/or sleep
maintenance. To accomplish this, the investigators will use a randomized double-blind
placebo-controlled crossover 8-week study design to examine the effect of suvorexant on sleep
physiology as assessed by polysomnography (PSG), actigraphy, circadian rhythm, and clinical
measures.